Abstract
While allogeneic hematopoietic stem cell transplantations have a curative potential, infections and graft-versus-host disease remain significant problems. The intestinal microbiota can influence responses to cancer chemotherapy and the role of the microbiota in affecting allogeneic hematopoietic stem cell transplantation outcomes is increasingly appreciated. The following paper discusses the most recent developments in this area.
Trial registration:
ClinicalTrials.gov NCT02269150.
Keywords:
Allo-HSCT; Bacteremia; Diversity; Intestinal microbiota; Metronidazole; Microbial dominance; Mortality; Survival.
Copyright © 2015 Elsevier Ltd. All rights reserved.
MeSH terms
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Bacteremia / drug therapy*
-
Bacteremia / etiology
-
Bacteremia / microbiology
-
Bacteremia / mortality
-
Clinical Trials as Topic
-
Gastrointestinal Microbiome*
-
Graft vs Host Disease / microbiology
-
Graft vs Host Disease / mortality
-
Graft vs Host Disease / pathology
-
Graft vs Host Disease / prevention & control*
-
Hematologic Neoplasms / microbiology
-
Hematologic Neoplasms / mortality
-
Hematologic Neoplasms / pathology
-
Hematologic Neoplasms / therapy*
-
Hematopoietic Stem Cell Transplantation / mortality*
-
Humans
-
Metronidazole / administration & dosage
-
Metronidazole / adverse effects
-
Opportunistic Infections / drug therapy*
-
Opportunistic Infections / etiology
-
Opportunistic Infections / microbiology
-
Opportunistic Infections / mortality
-
Risk Factors
-
Survival Analysis
-
Vancomycin / administration & dosage
-
Vancomycin / adverse effects
-
Vancomycin-Resistant Enterococci / growth & development
-
Vancomycin-Resistant Enterococci / pathogenicity
Substances
-
Anti-Bacterial Agents
-
Antineoplastic Agents
-
Metronidazole
-
Vancomycin
Associated data
-
ClinicalTrials.gov/NCT02269150